Recent studies have reported the role of the TTYH3/MK5 axis in regulating GSK‐3β/β‐catenin signaling in hepatocellular carcinoma,14 and its involvement in bladder cancer progression through the FGFR1/H‐Ras/A‐Raf/MEK/ERK pathway.15 This evidence concerns the gene HRAS and urinary bladder carcinoma.